Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.15 - $79.96
Previous CloseN/A
Volume7.58M
Average Volume (3M)8.98M
Market Cap
$9.37B
Enterprise Value$6.31B
Total Cash (Recent Filing)$5.13B
Total Debt (Recent Filing)$741.00M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Oct 30, 2025EPS Estimate
-2.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding389,079,740
10 Day Avg. Volume9,813,283
30 Day Avg. Volume8,984,061
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$46.00Price Target Upside90.95% Upside
Rating ConsensusHold
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Cost ManagementAggressive cost cuts across the organization are promising signs that MRNA is taking steps to optimize its cost structure.
Financial PerformanceMRNA reported a 2Q topline beat driven by Spikevax, with product revenue of $114mn, which was above consensus estimates.
Vaccine ApprovalsThe FDA announced approval of multiple COVID-19 vaccines that have updated monovalent formulations to target the LP.8.1 variant, including both of Moderna’s COVID-19 mRNA vaccines.
Bears Say
Market ChallengesAnalyst maintains an Underperform rating due to persistent key challenges and uncertainties over the long-term growth outlook.
Revenue GuidanceMRNA lowered the upper-end of FY25 product revenue guidance to $1.5bn-$2.2bn from $1.5bn-$2.5bn prior due to a timing shift of deliveries of contracted revenue for the UK into 1Q26.
Workforce ReductionThe announcement of a workforce reduction of about 10% indicates a significant restructuring effort.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $23.15 and its highest was $79.96 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $9.37B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 30, 2025 which is in 59 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Aug 01, 2025. The company reported -$2.13 earnings per share for the quarter, beating the consensus estimate of -$2.989 by $0.859.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.05.
How many shares outstanding does Moderna have?
Moderna has 389,079,740 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.13 in its last earnings report, beating expectations of -$2.989. Following the earnings report the stock price went down -6.631%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$46.00 (90.95% Upside)
$46.00 (90.95% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.95%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
-23.41%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant progress in vaccine approvals and cost reductions, but these were offset by declining revenues, financial losses, and a workforce reduction. While Moderna is making strides in its strategic priorities, the challenges in revenue and operational adjustments indicate uncertainty in the near term.View all MRNA earnings summariesMRNA Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
MRNA Stock 12 Month Forecast
Average Price Target
$46.00
▲(90.95% Upside)
Technical Analysis
Ownership Overview
7.74% Insiders
19.71% Mutual Funds
16.59% Other Institutional Investors
32.25% Public Companies and Individual Investors